The Obesity Drug That Makes Surgery Look Like a Warm-Up
Lilly's triple-agonist retatrutide posted 30% weight loss at two years, rivaling bariatric surgery and leaving Pfizer and Roche scrambling to differentiate at ADA 2026. The competitive hierarchy in obesity drugs just got a whole lot clearer.
A Number That Changes Everything
Forget everything you thought about the ceiling for weight-loss drugs. At this year's American Diabetes Association meeting in San Francisco, Eli Lilly dropped a number that made the entire obesity drug world sit up straight: 30.3% body weight lost over two years.
That's not a typo. Lilly's triple agonist retatrutide, which targets three hormone receptors simultaneously (GIP, GLP-1, and glucagon), posted Phase 3 results that rival gastric bypass surgery. In the TRIUMPH-1 trial, patients on the highest dose lost an average of 85 pounds by week 104, and the weight-loss curve still hadn't flattened.
If semaglutide (Ozempic/Wegovy) was the iPhone moment for obesity medicine, retatrutide might be the iPhone Pro Max. And ADA 2026 made it clear that everyone else is scrambling to figure out where they fit.
Why Three Receptors Beat Two
Most GLP-1 drugs on the market work by mimicking a single gut hormone that tells your brain you're full. Lilly's tirzepatide (Mounjaro/Zepbound) upped the ante by hitting two receptors: GLP-1 and GIP. Retatrutide adds a third target, glucagon, and that's where things get interesting.
Think of it like a weight-loss strategy with two levers instead of one. GLP-1 and GIP suppress your appetite; they convince your brain the kitchen is closed. Glucagon does something different entirely: it cranks up your body's calorie-burning furnace, pushing fat cells to release and oxidize their stored energy.
The result? Patients in TRIUMPH-1 didn't just eat less. They burned more. At 80 weeks on 12 mg, the average participant shed 28.3% of their body weight (about 70 pounds). Nearly half hit the 30% weight-loss mark, a threshold historically reserved for bariatric surgery patients.
The metabolic ripple effects were just as striking. Triglycerides dropped by up to 41%. Systolic blood pressure fell by 12 points. Waist circumference shrank by 9.5 inches. This isn't just a skinny drug; it's a cardiovascular overhaul.
Get tomorrow's biotech intelligence before your competitors.
Join thousands of biotech professionals who start their day with our free, daily briefing.
Retatrutide wasn't content to dominate only obesity headlines. Lilly also presented TRANSCEND-T2D-1, a 40-week trial in 537 people with early type 2 diabetes.
The glycemic results were eye-popping. Patients saw their A1c (a measure of long-term blood sugar control) drop by up to 2 full percentage points. Nearly 90% reached the standard A1c target below 7%, and 46% hit below 5.7%, which is technically the "normal" range. If your A1c is normal, do you even still have diabetes? That's the kind of question these data invite.
Weight loss in the diabetes population was strong too: 16.8% at 40 weeks, with no sign of leveling off.
But there's one wrinkle Lilly can't ignore. Among the 403 retatrutide-treated patients in TRANSCEND-T2D-1, 7 experienced irregular heartbeats versus zero on placebo. Three had serious cardiovascular complications. The numbers are small, but when the comparator is zero, regulators notice. Expect a dedicated cardiovascular outcomes trial before this drug gets anywhere near a broad diabetes label.
Pfizer's Pivot: From Stumble to Strategy
Meanwhile, Pfizer showed up to ADA with something to prove. Its oral GLP-1 attempt, danuglipron, flamed out spectacularly: over 50% of obesity trial participants on the drug dropped out, many because of brutal GI side effects, and only about 39% of participants overall completed treatment. Pfizer pulled the plug on the entire program.
But Pfizer didn't come to ADA to dwell on the past. Instead, the company unveiled Phase 2b data for berobenatide, a long-acting injectable GLP-1 that it's calling a "foundational medicine." The pitch: berobenatide could serve as a backbone therapy, paired with other hormone agonists the way a reliable starter anchors a basketball rotation.
The early numbers are respectable, if not jaw-dropping. At 60 weeks, a high weekly dose produced about 16% weight loss. That puts it in the same neighborhood as semaglutide, which is solid, but it's roughly half of what retatrutide just posted. Pfizer is betting that combinations (adding GIP or amylin agonists on top) will close the gap. With roughly 10 Phase 3 trials planned, the company is clearly playing the long game.
Roche: Best in Class, or Just More of the Same?
Roche brought 48-week Phase 2 data for enicepatide (CT-388), a dual GLP-1/GIP agonist it acquired through the Carmot Therapeutics deal. On paper, the results look competitive: 22.5% placebo-adjusted weight loss at 48 weeks, no plateau, and a tolerable safety profile.
The problem? Mechanistically, enicepatide is almost identical to tirzepatide. Both are once-weekly injectable dual agonists. Roche's version uses "cAMP signal-biased" agonism (a subtly different way of activating the same receptors), but that distinction hasn't translated into a clear clinical advantage yet. No better tolerability data. No superior convenience. No oral option.
In a world where Lilly just showed 30% weight loss with a triple agonist, launching another dual agonist feels a bit like releasing a flip phone after the smartphone already shipped. Roche knows this, which is why it's simultaneously developing petrelintide, an amylin analog that could be combined with enicepatide for additive effects. The real play is the combo; the monotherapy is just the opening act.
The Bigger Picture: A Three-Tier Race
ADA 2026 crystallized the competitive hierarchy in obesity medicine into something remarkably clear:
Tier 1: Lilly. Retatrutide's triple-agonist data are in a class by themselves. Combined with tirzepatide (with Zepbound already outselling Wegovy in U.S. obesity prescriptions) and the newly approved oral pill orforglipron, Lilly has a full product lineup spanning injectable blockbusters, next-gen biology, and primary-care-friendly pills.
Tier 2: Novo Nordisk. Still a powerhouse with semaglutide across injectable and oral formulations, plus a cagrilintide/semaglutide combo (GLP-1 plus amylin) that showed strong results at ADA. But momentum has shifted. Novo is playing defense for the first time.
Tier 3: Everyone else. Pfizer and Roche are serious contenders with deep pockets, but their lead assets are years behind Lilly's and don't yet match its efficacy ceiling. They're building for 2028 and beyond.
The field is also evolving beyond simple "how much weight can you lose" comparisons. ADA 2026 featured dedicated sessions on amylin as a new therapeutic axis, muscle-preserving adjuncts, ultra-long-acting injectables, and oral small molecules. The next chapter won't just be about losing more pounds; it'll be about losing the right weight while protecting muscle, improving liver health, and preventing cardiovascular events.
What This Means for Your Portfolio (and Your Waistline)
The obesity drug market was supposed to be a $150 billion opportunity. Analysts have tempered that number as price cuts, Medicare negotiations, and competition compress margins. But the clinical story just got stronger. When a drug produces surgery-level results in a weekly injection, the addressable population doesn't shrink. It explodes.
Lilly's triple G is now the benchmark everyone has to beat. Pfizer and Roche have credible plans, but they're building the rocket while Lilly is already in orbit. The question isn't whether the obesity drug market will be massive. It's whether anyone besides Lilly can claim a meaningful share of it.
Clinical & Regulatory
5 min read
Prostate Cancer Just Got Its HER2 Moment
The FDA just approved the first targeted therapy for a specific genetic subtype of prostate cancer, turning PTEN loss from a bad prognosis into an actionable target. It's the same precision oncology playbook that transformed breast cancer, and it could reshape how we treat the most common male cancer.
